Tuesday, 17 November 2026 · Europe
EUR/USD 1.101 EUR/GBP 0.8345 EUR/CHF 0.9244 EUR/PLN 4.403 All rates →
Sign in · Join
EUROPES The European Report
European Edition Tuesday, 17 November 2026
LATEST Speed camera fault may have allowed drivers to escape fines Le Flash →
Tech & Startups

Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design

Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design

Isomorphic Labs, the Alphabet drug discovery company run by Demis Hassabis, has raised $5bn in a Series C round co-led by Greenoaks and Sequoia Capital. The company announced the round on Tuesday, six months after it raised $2.1bn in May. Andreessen Horowitz and several other new investors joined, with what Isomorphic called continued significant investment […] This story continues at The Next Web

Isomorphic Labs, the Alphabet drug discovery company run by Demis Hassabis, has raised $5bn in a Series C round co-led by Greenoaks and Sequoia Capital. The company announced the round on Tuesday, six months after it raised $2.1bn in May.

The company did not disclose its valuation, Bloomberg reported . Bloomberg had reported this month that the round would value Isomorphic at about $50bn .

Hassabis told Bloomberg’s Rebecca Torrence and Shirin Ghaffary that the money will speed up Isomorphic’s move towards clinical trials.

“What we’re trying to build is a platform to do hundreds of drugs a year,” Hassabis told Bloomberg.

Isomorphic said its drug design engine, IsoDDE, is producing positive preclinical results in its own oncology and immunology programmes and with partners. It has more than 20 programmes underway, Hassabis said. Its pharma partners include Eli Lilly, Novartis and Johnson & Johnson.

In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. He would not give Bloomberg an updated target. He said the company is on track with its regulatory submissions and will have more to announce in 2027. No regulator has yet approved an AI-designed drug, Bloomberg noted.

Isomorphic will also use the money to move beyond small-molecule drugs into “pretty much all modalities”, Hassabis said, including large-molecule biologics.

“Isomorphic Labs is building foundational technology for the future of medicine,” said Konstantine Buhler, a partner at Sequoia Capital.

Buhler told Bloomberg that Sequoia backed the company because Isomorphic has found scaling laws for its models. That means performance keeps improving with more computing power and data, he said.

The round is Isomorphic’s first since Hassabis stepped back as Google DeepMind’s chief executive in August, in an Alphabet shake-up . He is now DeepMind’s chair and Alphabet’s chief scientist, and remains Isomorphic’s chief executive.

He also addressed computing power. Jensen Huang’s resignation from Nvidia last week has some AI companies worried about their access to chips, Bloomberg reported. Google designs its own AI chips.

“We’ve got very secure compute pipelines,” Hassabis told Bloomberg.

Isomorphic started in 2021 to build on Google DeepMind’s AlphaFold protein structure model. It has its headquarters in London and offices in Cambridge, Massachusetts, and Lausanne.

More from Tech & Startups